Healthy
Conditions
Keywords
Beta2-adrenergic stimulation, Amino acid availability, Skeletal muscle hypertophy
Brief summary
The purpose of the project is to investigate the effect of amino acid availability on the muscle anabolic response to beta2-adrenergic stimulation in young healthy men and women.
Interventions
DRUGSalmeterol + amino acid availability
The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device and 40 g amino acid availability (clear whey in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
DRUGSalmeterol + placebo
The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
Sponsors
University of Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Thirty-six healthy, well-trained men and women will be randomized into three distinct groups, each receiving one of the following interventions: 1) salmeterol with amino acid availability, 2) salmeterol, or 3) a placebo, administered twice daily over a 6-week intervention period. This design aims to elucidate the impact of amino acid availability on the muscle anabolic response to beta2-adrenergic stimulation.
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-40 * Physically active \>5 hours a week * Maximum oxygen uptake classified as high or very high
Exclusion criteria
* Active smoker currently or within the past 5 years * Regular intake of medication deemed by the responsible study physician to affect the test parameters (hormonal contraception is accepted for women) * Chronic or acute illness deemed by the responsible study physician to affect the test parameters * Deviation from the study protocol * Lean mass index \>21 kg/m² * Pregnancy * Smoker * Blood donation during the past 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Skeletal muscle hypertrophy | Through study completion, an average on 7 weeks | Muscle hypertrophy measured using Dual-energy X-ray Absorptiometry (DXA). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quadriceps strength | Through study completion, an average on 7 weeks | Maksimal torque (Nm) achieved during isometric contraction |
| Power output during sprint testing | Through study completion, an average on 7 weeks | Power output measured in Watts during a sprint on a bike ergometer |
| Power output during time trial | Through study completion, an average on 7 weeks | Mean power output measured in Watts during a time trial on a bike ergometer |
Other
| Measure | Time frame | Description |
|---|---|---|
| Maximal oxygen uptake | Through study completion, an average on 7 weeks | Maximal oxygen uptake measured during an incremental test to exhaustion on a bike ergometer. |
Countries
Denmark
Outcome results
None listed